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Abstract: Given the important role of angiogenesis in liver pathology, the current study investigated
the role of Runt-related transcription factor 1 (RUNX1), a regulator of developmental angiogenesis,
in the pathogenesis of non-alcoholic steatohepatitis (NASH). Quantitative RT-PCRs and a transcription
factor analysis of angiogenesis-associated differentially expressed genes in liver tissues of healthy
controls, patients with steatosis and NASH, indicated a potential role of RUNX1 in NASH. The gene
expression of RUNX1 was correlated with histopathological attributes of patients. The protein
expression of RUNX1 in liver was studied by immunohistochemistry. To explore the underlying
mechanisms, in vitro studies using RUNX1 siRNA and overexpression plasmids were performed in
endothelial cells (ECs). RUNX1 expression was significantly correlated with inflammation, fibrosis
and NASH activity score in NASH patients. Its expression was conspicuous in liver non-parenchymal
cells. In vitro, factors from steatotic hepatocytes and/or VEGF or TGF-β significantly induced the
expression of RUNX1 in ECs. RUNX1 regulated the expression of angiogenic and adhesion molecules
in ECs, including CCL2, PECAM1 and VCAM1, which was shown by silencing or over-expression
of RUNX1. Furthermore, RUNX1 increased the angiogenic activity of ECs. This study reports that
steatosis-induced RUNX1 augmented the expression of adhesion and angiogenic molecules and
properties in ECs and may be involved in enhancing inflammation and disease severity in NASH.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) includes a wide compass of liver pathologies,
ranging from simple steatosis, usually a mild, benign and non-progressive condition, to non-alcoholic
steatohepatitis (NASH), which may progress to liver cirrhosis and ultimately hepatocellular carcinoma
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(HCC). With NAFLD affecting both children and adults alike, it is postulated to emerge as the leading
cause of end-stage liver diseases in the coming years [1]. Several cellular and molecular events conspire
and collaborate to transform simple steatosis to NASH to HCC. However, the underlying precise
mechanisms of disease pathogenesis and NAFLD progression have just begun to be understood. Some
of the newly emerging concepts include iron overload, inflammation, dysregulated fat metabolism,
oxidative stress, gut microbiota and angiogenesis [2].
Angiogenesis or new blood vessel formation is a crucial aspect of inflammation and a critical
step in tissue damage, healing, and vascular remodeling. Changes in liver vascular architecture have
been linked to the progression of fibrosis, cirrhosis and HCC in chronic liver diseases (CLD) [3,4].
Almost all experimental and clinical conditions of CLD, including NASH, have been associated with
an over-expression of pro-angiogenic cytokines and related receptors. Although various studies
have reported an upregulation of angiogenic factors, particularly VEGF in NASH, the underlying
mechanisms that regulate angiogenesis, inflammation and fibrogenesis in NASH pathology remain
obscure [5–7].
In the current study, we explored the role of Runt-related transcription factor 1 (RUNX1) in the
pathogenesis of NASH. RUNX1, also known as acute myeloid leukemia 1 (AML1), is a powerful and
pivotal regulator of hematopoiesis and angiogenesis [8,9]. A defect in RUNX1 is associated with
impairment in angiogenesis accompanied by the absence of hematopoietic stem cells [10]. Given the
significance of RUNX1 in angiogenesis and its rarely identified role in NASH, we investigated the
expression and function of RUNX1 in NASH pathology by addressing its emergence in endothelial
cells (ECs).
2. Materials and Methods
2.1. Study Subjects and Collection of Samples
Human liver tissues were histologically examined for patients without NAFLD (n = 33),
patients with simple liver steatosis (n = 46) and patients with NASH (n = 43) as described earlier [11,12]
(for tissue characteristics see Supplementary Table S1). A subset of these samples was used for a mRNA
microarray analysis: patients without NAFLD (n = 7), patients with simple liver steatosis (n = 7),
and with non-alcoholic steatohepatitis (NASH) (n = 7). The experimental procedures were performed
according to the guidelines of the charitable state-controlled foundation HTCR (Human Tissue and
Cell Research, Regensburg, Germany), with written informed consent from patients. The study
in Germany and the consent form were approved by the local ethical committee of the University
of Regensburg (ethics statement 12-101-0048, University of Regensburg, Germany). Additionally,
immunohistochemistry (IHC) studies were conducted on liver biopsies collected from NASH patients’
samples (n = 16) and control liver tissues (n =10) collected in ILBS, New Delhi (for patient characteristics
see Supplementary Table S2). The study performed in India was duly approved by the Human ethics
committee of ILBS, New Delhi (ethics approval F25/5/64/ILBS/AC2014/1484). All experiments involving
human tissues and cells were carried out in accordance to The Code of Ethics of the World Medical
Association (Declaration of Helsinki).
2.2. Differential Gene Expression Studies and qRT-PCRs
About 17 differentially expressed genes (DEGs) obtained from a microarray experiment and
associated with gene ontology (GO) term angiogenesis were selected for further Taqman quantitative
real time-PCR (qRT-PCR) validation studies (Supplementary Table S3A) using a larger cohort of
NAFLD liver tissue samples (Supplementary Table S1). For in vitro assays, SYBR Green PCR master
mix (Applied Biosystems, Foster City, CA, USA) based qRT-PCR studies were done (Supplementary
Table S3B).
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2.3. Immunohistochemistry Analysis
Samples of human liver tissues were fixed and stained as per standard protocols. IHC scoring
was done on a scale of 1–4 by counting RUNX1 positive cells per field. Details of the protocols and
antibodies used are given in the supplementary material and Supplementary Table S4.
2.4. Culture of Endothelial Cells with Conditioned Medium from Hepatoma Cells Treated with Palmitic Acid
Huh7 cells or mouse primary hepatocytes were treated with 200µM palmitic acid-BSA (PA) for 48 h
according to previously published methods [13]. BSA treated cells served as controls. To investigate
the effect of steatotic liver cells on gene expression, human umbilical vein endothelial cells (HUVECs)
or LSECs (mouse) were incubated with conditioned medium (CM) from BSA/PA treated Huh7 cells
or primary hepatocytes, respectively, for 24 h and then assayed for gene expression. For validation
of VEGF in the induction of RUNX1 gene expression, studies were also conducted by adding VEGF
blocking antibody in HUVECs along with CM from BSA/PA treated Huh7 cells.
2.5. Induction of RUNX1 Expression in HUVECs
To study induction of RUNX1 expression in HUVECs, HUVECs were treated with or without
10 ng/mL VEGF (Himedia Laboratories, Mumbai, India) or TGF-β for 24 h. After 24 h, cells were
trypsinized for analysis of RUNX1 gene expression in unstimulated and stimulated cells.
2.6. RUNX1 Inhibition and Overexpression in HUVECs
To elucidate the role of RUNX1 in inflammation and angiogenesis, steatotic or activated HUVECs
were transfected with 50 nmol/mL × 106 cells of either negative control (NC) siRNA (Catalogue
no# AM4635) or pre-designed RUNX1-specific siRNA (siRNA ID: s229352) (Thermofisher Scientific,
Waltham, MA, USA) using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Forty-eight hours after transfection, cells were analyzed by qRT-PCR to
confirm the knockdown of RUNX1. For overexpression studies, HUVECs were transfected with 2µg/L
× 106 cells of control plasmid (pControl, empty vector) or RUNX1 plasmid (pcDNA3.1+ /C-(K)-DYK
vector with RUNX1b, Gene Script # OHu26354), referred to as pRUNX1, in the absence or presence
of 10 ng/mL VEGF. For transfection, lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used
according to the manufacturer’s instructions. pcDNA3-EGFP plasmid vector (kind gift from Dr. Vijay)
was used as the control of transfection efficiency and expression in all the transfection experiments.
Forty-eight hours after plasmid transfection, cells were analyzed by qRT-PCR. HUVECs with loss
of RUNX1 or gain of RUNX1 expression were assayed for gene expression of adhesion molecules,
angiogenic markers by qRT-PCR, flow cytometry and angiogenic functions by matrigel assays. CCL2
levels were assayed by ELISA in HUVECs under different conditions.
2.7. Flow Cytometry Analysis
The labeled antibodies used for flow cytometry are given in Supplementary Table S4. After
antibody incubation in PBS for 45 min at 4 ◦C, the cells were fixed with paraformaldehyde in PBS.
Multicolor flow cytometry was performed using FACS Verse (BD Biosciences, San Jose, CA, USA) and
minimum of 1 million events using live cells were acquired. Analysis of flow cytometry data was
performed using Flow-Jo v10 software (BD Biosciences, San Jose, CA, USA). Unstained cells without
any antibody were used as negative controls.
2.8. Statistical Analysis
PCR data obtained from patient samples were evaluated for normality distribution by a
Shapiro–Wilk test. Statistical differences between the two groups were analyzed by a two-tailed
Mann–Whitney U Test or a Student's unpaired t-test (in vitro and flow cytometry experiments) and
statistical differences between several groups (data from human samples) by a Kruskal–Wallis Test
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(SPSS Statistics program, IBM, Leibniz Rechenzentrum, München, Germany). A value of p < 0.05
was regarded as significant. The Pearson correlation (r) was calculated using the IBM SPSS Statistics
program. Each experiment was performed in at least triplicates and data were expressed as means ± SD
(standard deviation).
More details and description of additional methods are summarized in Supplementary Files.
3. Results
3.1. Expression of Transcription Factor RUNX1 is Increased in NAFLD Controlling Differentially Expressed
Genes (Degs) Associated with Angiogenesis
In a preliminary microarray study, we compared mRNA expression in either groups of control (N
or normal liver), steatosis (S) and NASH (SH) and identified differentially expressed genes (DEGs)
followed by a gene enrichment analysis to identify GO-categories. A subset of 17 DEGs associated with
GO-terms angiogenesis and in part with hypoxia and lipid metabolism was selected (Supplementary
Table S5), and together with known angiogenic genes (VEGFA, FLT1/VEGFR1, KDR/VEGFR2, CXCR4,
PPARγ) [3] further analyzed in a validation study using qRT-PCR. By comparison of the relative mRNA
expression of the three groups, N, S and SH, we could confirm a significant differential expression of
several genes, but not all in a larger cohort of liver tissue samples (Table 1 and Supplementary Table
S6). Among the confirmed DEGs, we found transcription factor RUNX1, quite recently described to
regulate stellate cell activation in NASH [14], and known targets of RUNX1 comprised of CCL2, NOS3
(eNOS), PI3KCA and PRKCE. Intriguingly, among the genes, which were not significantly different
among the controls and patient groups, were typical angiogenic genes VEGFA, VEGFR1 and VEGFR2
(Supplementary Table S6).
Table 1. Analysis of mRNA expression of genes associated with angiogenesis in resected hepatic tissue
samples of patients with normal liver (N), steatosis (S) and non-alcoholic steatohepatitis (NASH). Data
are shown as means ± SD and statistical differences were analyzed by pairwise comparison using a
Kruskal–Wallis Test.
Relative mRNA Expression p-Value
Gene N (n = 33) S (n = 46) NASH (n = 43) N/S N/SH S/SH
CCL2 1.82 ± 1.47 2.30 ± 1.63 3.74 ± 2.13 0.534 0.000 0.002
CXCL8 (IL8) 4.33 ± 4.5 7.16 ± 8.99 16.97 ± 17.18 0.404 0.000 0.002
CXCR4 1.57 ± 1.18 2.63 ± 1.70 2.87 ± 1.84 0.008 0.002 1.000
EREG 2.87 ± 2.26 5.34 ± 4.86 7.48 ± 6.19 0.197 0.001 0.285
FASN 3.27 ± 2.07 6.35 ± 5.75 5.67 ± 5.27 0.048 0.077 1.000
HOMX1 (HO1) 0.71 ± 0.36 0.67 ± 0.39 0.95 ± 0.66 1.000 0.126 0.024
NOS3 (eNOS) 0.72 ± 0.32 0.82 ± 0.52 1.12 ± 0.74 1.000 0.011 0.040
PIK3CA 0.61 ± 0.21 0.98 ± 1.22 0.81 ± 0.25 0.013 0.001 1.000
PPARγ 0.61 ± 0.24 0.73 ± 0.34 0.97 ± 0.47 0.552 0.001 0.034
PRKCE 0.71 ± 0.34 0.96 ± 0.42 1.00 ± 0.60 0.004 0.014 1.000
PROK2 2.55 ± 2.17 3.66 ± 4.13 6.49 ± 7.96 1.000 0.058 0.182
RUNX1 1.75 ± 1.21 1.90 ± 1.56 3.38 ± 2.55 1.000 0.000 0.002
3.2. RUNX1 Expression Correlates with the Severity of NAFLD
The transcription of RUNX1 gene is regulated by differential splicing and promoter utilization,
which results in three major isoforms: RUNX1a, RUNX1b and RUNX1c [15]. In all the NAFLD samples
analyzed in this study, we found RUNX1b as the predominant isoform (data not shown) and therefore,
total RUNX1 expression levels correspond to RUNX1b. To analyze the relevance of RUNX1 mRNA
expression with regard to disease progress in our patients, its correlation analysis was performed
with the histopathological NASH activity score (NAS), the grade of steatosis, as well as inflammation,
and the fibrosis score. RUNX1 mRNA expression demonstrated a significant positive correlation
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with NAS, steatosis and inflammation degree (Figure 1A–D). In addition to RUNX1, other validated
DEGs (Table 1) showing significant correlations with histopathological disease progress are shown in
Supplementary Figure S1A–D. RUNX1 target genes, CCL2 and PIK3CA significantly correlated to NAS,
steatosis, inflammation grade and fibrosis score, NOS3 to NAS and inflammation grade and PRKCE to
NAS and steatosis grade.
Cells 2019, 8, 1277 5 of 13 
 
was performed with the histopathological NASH activity score (NAS), the grade of steatosis, as 
well as inflammation, and the fibrosis score. RUNX1 mRNA expression demonstrated a significant 
positive correlation with NAS, steatosis and inflammation degree (Figure 1A–D). In addition to 
RUNX1, other validated DEGs (Table 1) showing significant correlations with histopathological 
disease progress are shown in Supplementary Figure S1A–D. RUNX1 target genes, CCL2 and 
PIK3CA significantly correlated to NAS, steatosis, inflammation grade and fibrosis score, NOS3 to 
NAS and inflammation grade and PRKCE to NAS and steatosis grade.  
r = 0.369
p < 0.001
0 1 2 3 4
0
3
6
9
12
15
NASH activity score
Re
l. R
UN
X1
 m
RN
A
ex
pr
es
sio
n(A)
0 1 2 3
0
3
6
9
12
15
steatosis grade
Re
l. R
UN
X1
 m
RN
A 
ex
pr
es
sio
n r = 0.248
p < 0.01
(B)
Re
l. R
UN
X1
 m
RN
A
ex
pr
es
sio
n
Inflammation grade
0 1 2 3
0
3
6
9
12
15
r = 0.385
p < 0.001
(C)
0 1 2 3 4
0
3
6
9
12
15
grade of fibrosis
Re
l. R
UN
X1
  m
RN
A 
ex
pr
es
sio
n r = 0.199
p = 0.083
(D)
 
Figure 1. Correlation between RUNX1 mRNA expression and histopathological parameters. 
Expression of RUNX1 mRNA was analyzed by qRT-PCR in liver tissue samples from patients with 
NASH (n = 43), hepatic steatosis (n = 46) and normal liver tissue (n = 33) and correlated to 
histopathologic proven (A) NASH activity score (B) steatosis grade (C) inflammation grade and (D) 
fibrosis grade. HPRT mRNA expression was determined for normalization, statistical differences 
between several grades were analyzed by Kruskal-Wallis Test (p < 0.05 was considered significant) 
and ‘r’ denotes the Pearson’s correlation coefficient. 
To study RUNX1 protein expression, we performed an IHC analysis of RUNX1 in NASH liver 
biopsies. NASH patients showed varying degrees of RUNX1 protein expression in the liver (Figure 
2A). RUNX1 nuclear positivity was almost absent in parenchymal cells and well evident in liver 
NPCs, presumably among others in ECs and hepatic stellate cells. Negative antibody controls (with 
RUNX1 antibody and without secondary antibody) are shown in Supplementary Figure S2. 
Furthermore, RUNX1 expression was significantly positively correlated with fibrosis score (r = 0.80, 
p < 0.001), NAS (r = 0.77, p < 0.001) and inflammatory grade (r = 0.79, p < 0.01) in NASH liver tissues 
(Figure 2B–D) and therefore correlates with NASH disease severity. In addition, RUNX1 protein 
expression (IHC scores) in the liver tissues of NASH patients were significantly positively 
correlated with its liver mRNA expression (r = 0.81, p < 0.001, Figure 2E). 
Figure 1. Correlation betweenRUNX1mRNA expression and histopathological parameters. Expression
of RUNX1 mRNA was analyzed by qRT-PCR in liver tissue samples from patients with NASH (n = 43),
hepatic steatosis (n = 46) and normal liver tissue (n = 33) and correlated to histopathologic proven
(A) NASH activity score (B) steatosis grade (C) inflammation grade and (D) fibrosis grade. HPRT mRNA
expression was determined for normalization, statistical differences between several grades were
analyzed by Kruskal-Wallis Test (p < 0.05 was considered significant) and ‘r’ denotes the Pearson’s
correlation coefficient.
To study RUNX1 protein expression, we performed an IHC analysis of RUNX1 in NASH liver
biopsie . NASH patients show d varying degrees of RUNX1 protein expression in the liver (Figure 2A).
RUNX1 nuclear positivity was almost abs nt in parenchymal cells and well evident in liver NPCs,
presumably among others in ECs nd hepatic st llate cells. Negative antibody controls (with RUNX1
antibody and without sec ndary antibody) are shown in Supplementary Figure S2. Fu thermore,
RUNX1 expression was significantly positively c rrelated with fibrosis scor (r = 0.80, p < 0.001),
NAS ( = 0.77, p < 0.001) and inflammatory gr de (r = 0.79, p< 0.01) in NASH liver tissues (Figure 2B–D)
and therefore correlates with NASH disease severity. In addition, RUNX1 protein expression (IHC
scores) in the liver tissues of NASH patients were significantly positively correlated with its liver
mRNA expression (r = 0.81, p < 0.001, Figure 2E).
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Figure 2. Immunohistochemical (IHC) analysis of RUNX1 expression in NASH patients. (A) RUNX1 
immunostained images (20× objective) with an increasing number of brown nuclear immuno-
positive cells (score 1–4). RUNX1 positivity was mostly observed in the non-parenchymal cells. 
Hematoxylin stained nuclei were distinguishable from RUNX1-positive brown nuclei. (B) 
Correlation between RUNX1 IHC and NASH activity score (n = 16), (C) RUNX1 IHC score and 
fibrosis grade (n = 16), and (D) RUNX1 IHC score and inflammatory grade (n = 16) in NASH 
patients. (E) Correlation between RUNX1 mRNA and its IHC score in liver tissues of patients (n = 
16). The Pearson correlation (r) and statistical significance (p) were calculated. 
3.3. Palmitic Acid Treated Huh7 Cells Release VEGF and TGF-β-Inducing RUNX1 Gene Expression in ECs  
To investigate if steatosis induces RUNX1 expression, studies were further carried out in in 
vitro models of NAFLD. PA treatment of Huh7 cells led to significant increases of lipid droplets in 
these cells visualized by BODIPY staining (Supplementary Figure S3A). Analysis of mRNA 
expression of BSA treated control cells (BSA-Huh7) and Huh7 cells treated with PA (PA-Huh7) 
revealed a low but significant increase in the expression of CCL2, CXCL8, PPARγ and PRKCE 
(Figure 3A), of which the latter was also significantly enhanced in steatotic compared to normal 
human liver samples (Table 1). Of note, RUNX1 expression was not altered by PA treatment in 
Huh7 cells. Therefore, in addition to the expression of some angiogenic genes in steatotic 
hepatocytes, other hepatic cells may contribute to a greater extent to angiogenic gene expression in 
NASH tissue.  
Moreover, HUVECs maintained for 24 h in culture medium (CM) from Huh7 cells treated with 
PA or BSA demonstrated a substantial upregulation of RUNX1 and its target gene CCL2, as well as 
the angiogenic gene expression of CXCR4, VCAM1, VEGFR1 and PRKCE after treatment with CM 
from PA-Huh7 cells (Figure 3B). To verify the impact of CM from PA-Huh7 cells on RUNX1 
expression, HUVECs were solely incubated with 200 µM PA, showing a moderate increase of 
RUNX1 mRNA expression compared to the control cells, but considerably less than in PA-Huh7 
CM treated HUVECs (Supplementary Figure S3B). However, only the PA treatment of HUVECs 
Figure 2. I unohistoche ical (I C) analysis of R X1 expression in S patients. ( ) R X1
i unostained images (20× objective) with an increasing number of brown nuclear immuno-positive
cells (score 1–4). RUNX1 positivity was mostly observed in the non-parenchymal cells. He atoxylin
stained nuclei were distinguishable from RUNX1-positive brown nuclei. (B) Correlation between
RUNX1 IHC and NASH activity score (n = 16), (C) RUNX1 IHC score and fibrosis grade (n = 16),
and (D) RUNX1 IHC score and inflammatory grade (n = 16) in NASH patients. (E) Correlation between
RUNX1 mRNA and its IHC score in liver tissues of patients (n = 16). The Pearson correlation (r) and
statistical significance (p) were calculated.
3.3. Palmitic Acid Treated Huh7 Cells Release VEGF and TGF-β-Inducing RUNX1 Gene Expression in ECs
To investigate if steatosis induces RUNX1 expression, studies were further carried out in in vitro
models of NAFLD. PA treatment of Huh7 cells led to significant increases of lipid droplets in these
cells visualized by BODIPY staining (Supplementary Figure S3A). Analysis of mRNA expression of
BSA treated control cells (BSA-Huh7) and Huh7 cells treated with PA (PA-Huh7) revealed a low but
significant increase in the expression of CCL2, CXCL8, PPARγ and PRKCE (Figure 3A), of which the
latter was also significantly enhanced in steatotic compared to normal human liver samples (Table 1).
Of note, RUNX1 expression was not altered by PA treatment in Huh7 cells. Therefore, in addition to
the expression of some angiogenic genes in steatotic hepatocytes, other hepatic cells may contribute to
a greater extent to angiogenic gene expression in NASH tissue.
Cells 2019, 8, 1277 7 of 14
Cells 2019, 8, 1277 7 of 13 
 
resulted in enhanced cell death and hence, this setup was not used in further assays (data not 
shown). Furthermore, we confirmed our results in mouse LSECs incubated with CM from primary 
mouse hepatocytes treated with PA for 24 h, showing a more than two-fold increase in the 
expression of RUNX1 mRNA compared to control cells (Supplementary Figure S3C).  
Re
l. m
RN
A 
ex
pr
es
sio
n i
n  
Hu
h7
 ce
lls
0
1
2
3
4
*
** ** **
(A)
0
1
2
3
4
Re
l. m
RN
A 
ex
pr
es
sio
n 
in
 H
IU
VE
Cs
*
**
* *
**
**
(B)
0
2
4
6
8
10
VEGF TGF-β
Re
l. R
UN
X1
 m
RN
A 
ex
pr
es
sio
n(D) **
**
0
0,2
0,4
0,6
0,8
1
CM BSA-CM PA-CM
VEGF
PDGF-BB
TGF-β
Co
nc
en
tra
tio
n [
ng
/m
l]
*
*
(C)
 
Figure 3. RUNX1 and angiogenic gene expression in endothelial cells maintained in conditioned 
medium (CM) from palmitic acid (PA) treated hepatoma (Huh7) cells. (A) Huh7 cells treated with 
0.2 mM PA for 48 h were analyzed for mRNA expression of RUNX1 and genes identified as 
angiogenesis associated DEGs in human NASH samples. The dotted line represents the control 
showing gene expression in Huh7 cells treated with BSA (n = 4). (B) HUVECs incubated with CM 
from PA-Huh7 cells were analyzed for mRNA expression of RUNX1, its target and angiogenic 
genes. The dotted line represents control, showing gene expression in HUVECs treated with CM 
from BSA-Huh7 cells (n = 4). 18S RNA expression was used for normalization. (C) Huh7 cells were 
treated with BSA or PA or CM alone and analyzed for the release of VEGF, PDGF-BB and TGF-β 
(pg/mL) (n = 3). (D) Relative RUNX1 mRNA expression in HUVECs treated with VEGF and TGF-β 
(10 ng/mL each) for 24 h. Un-induced cells without any manipulation were used as respective 
controls (Dotted line) (n = 3). 18S RNA expression was used for normalization. Data represent mean 
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Then, we analyzed the CMs of PA treated hepatoma cells for angiogenic factors, potentially 
regulating RUNX1 expression, such as VEGF, PDGF-BB and TGF-β, well known for their 
proangiogenic and fibrogenic role [16]. Out of the three factors analyzed, both VEGF and TGF-β 
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expression in Huh7 cells treated with BSA (n = 4). (B) HUVECs incubated with CM from PA-Huh7
cells were analyzed for mRNA expressi n of RUNX1, its target and angiogenic genes. The dotted line
represents control, showing gene expression in HUVECs treated with CM from BSA-Huh7 cells (n = 4).
18S RNA expression was used for normalization. (C) H h7 cells were treated with BSA or PA or CM
alone and analyzed for the release of VEGF, PDGF-BB and TGF-β (pg/mL) (n = 3). (D) Relative RUNX1
mRNA expression in HUVECs treated with VEGF and TGF-β (10 ng/mL each) for 24 h. Un-induced
cells without any manipulation were used as respective controls (Dotted line) (n = 3). 18S RNA
expression was used for normalization. Data represent mean ± SD. * p < 0.05; ** p < 0.001.
Moreover, HUVECs maintained for 24 h in culture medium (CM) from Huh7 cells treated with
PA or BSA demonstrated a substantial upregulation of RUNX1 and its target gene CCL2, as well as
the angiogenic gene expression of CXCR4, VCAM1, VEGFR1 and PRKCE after treatment with CM
from PA-Huh7 cells (Figure 3B). To verify the impact of CM from PA-Huh7 cells on RUNX1 expression,
HUVECs were solely incubated with 200 µM PA, showing a moderate increase of RUNX1 mRNA
expression compared to the control cells, but considerably less than in PA-Huh7 CM treated HUVECs
(Supplementary Figure S3B). However, only the PA treatment of HUVECs resulted in enhanced
cell death and hence, this setup was not used in further assays (data not shown). Furthermore, we
confirmed our results in mouse LSECs incubated with CM from primary mouse hepatocytes treated
with PA for 24 h, showing a more than two-fold increase in the expression of RUNX1 mRNA compared
to control cells (Supplementary Figure S3C).
Then, we analyzed the CMs of PA treated hepatoma cells for angiogenic factors, potentially
regulating RUNX1 expression, such as VEGF, PDGF-BB and TGF-β, well known for their proangiogenic
and fibrogenic role [16]. Out of the three factors analyzed, both VEGF and TGF-βwere significantly
enhanced in the PA-treated CM of hepatoma cells in comparison to BSA-treated conditioned media after
Cells 2019, 8, 1277 8 of 14
24 h of incubation (Figure 3D). However, levels of PDGF-BB were barely detected (Figure 3C). Next,
we studied the effect of both VEGF and TGF-β on the gene expression of RUNX1 in HUVECs. At similar
concentrations (10 ng/mL), both VEGF and TGF-β substantially upregulated the gene expression of
RUNX1 in the HUVECs as compared to the respective non-induced control cells (Figure 3D). Treatment
with VEGF antibody reduced the expression of RUNX1 mRNA by about 60% in HUVECs incubated
with CM from PA-Huh7 cells in comparison to that seen in untreated cells under the same conditions
(Supplementary Figure S3D). VEGF was used as one of the positive controls and a stimulator of RUNX1
expression in further studies. In conclusion, RUNX1 expression is not induced in hepatoma cells
by PA treatment, but in ECs, mainly through VEGF and TGF-β, released from hepatoma cells after
PA treatment.
3.4. RUNX1 Enhances Expression of Angiogenic Markers and Adhesion Molecules in HUVECs
To study the effects of RUNX1 expression on endothelial cell phenotype, we performed both RUNX1
knock-down and overexpression studies in HUVECs. For the RUNX1 knock-down, we attenuated
RUNX1 gene expression in HUVECs treated with CM from PA-Huh7 throughRUNX1 siRNA, which led
to a more than 50% reduction in RUNX1 mRNA expression in HUVECs compared with NC siRNA
(Figure 4A, Supplementary Figure S4A) (RUNX1 siRNA1 is further described as RUNX1 siRNA).
In comparison to controls, RUNX1 knockdown conditions led to a significant decrease in the expression
of VEGFR1 and RUNX1 target genes, including PRKCE and PI3KCA in HUVECs cultured with
CM from PA-Huh7 (Figure 4A). Hypothesizing the role of RUNX1 in endothelial cell mediated
inflammation and leukocyte infiltration, we also evaluated the expression of adhesion molecules
and chemotactic factor CCL2 (target gene of RUNX1) in HUVECs. When HUVECs were treated
with RUNX1 siRNA, expression of VCAM1, PECAM1 and CCL2 was significantly downregulated
as compared to that observed in the controls (Figure 4A). On the other hand, transfection with
expression vector for RUNX1 (pRUNX1) led to a more than four-fold increase in the expression of
RUNX1 gene in the HUVECs compared to control vector transfected cells (Supplementary Figure S4B).
Furthermore, in HUVECs transfected with pRUNX1, mRNA expression of PECAM1, VCAM1 and CCL2
was markedly higher as compared to that in the controls (Figure 4B) and this was not enhanced by
additional VEGF treatment, except for ICAM1 expression. Although we did not study the underlying
mechanisms that lead to increased expression of these molecules by VEGF and RUNX1, an additive
effect observed after treatment with both VEGF + pRUNX1 suggests that VEGF may be acting through
both RUNX1-dependent and -independent mechanisms in inducing the expression of these molecules
in endothelial cells. In addition, these results were confirmed by protein expression analysis using flow
cytometry for PECAM1 and VCAM1 (Figure 4C, Supplementary Figure S5) as well as ELISA assay for
CCL2 (Figure 4D). Thus, RUNX1 can regulate the expression of adhesion molecules and chemotactic
factors, such as CCL2, in ECs.
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Figure 4. RUNX1 alters expression of angiogenic and adhesion molecules in endothelial cells (A)
HUVECs, treated with RUNX1 siRNA or NC siRNA and incubated with CM from PA-Huh7 cells,
were analyzed for mRNA expression (fold change) of angiogenic, adhesion molecule and RUNX1
target genes (n = 3). (B) HUVECs transfected with RUNX1 expression plasmid (pRUNX1), control
plasmid (pControl, i.e., empty vector) and/or incubated with VEGF (10 ng/mL) were analyzed for
mRNA expression of adhesion molecule and chemotactic genes. HUVECs without any treatment were
used as respective controls (Dotted line) (n = 3). 18S RNA expression was used for normalization. (C)
Quantitative analysis of flow cytometry from (C) is shown (n = 3). (D) CCL2 levels (pg/mL) in culture
media of HUVECs transfected with RUNX1 expression plasmid (pRUNX1), control plasmid (pControl,
empty vector) and/or incubated with VEGF (10 ng/mL) (n = 4). Data represent mean ± SD. * p < 0.05
and ** p < 0.001.
3.5. RUNX1 Increases Angiogenic Activity of HUVECs
Next, we analyzed if the angiogenic ability of HUVECs was also governed by RUNX1. HUVECs
treated with VEGF and/or transfected with pRUNX1 had a substantially augmented angiogenic ability
compared to HUVECs transfected with control plasmid, in terms of increased branch points and
tube length (Figure 5A–C). The matrigel tube formation ability of HUVECs was also enhanced when
cultured in CM from PA-Huh7 cells as compared to that when treated with CM from BSA-Huh7 cells
(Supplementary Figure S6A). Both the number of branch points and tube length were increased in
the HUVECs after treatment with CM from PA-Huh7 cells and this enhancement was significantly
abrogated by additional treatment with RUNX1 siRNA (Supplementary Figure S6A–C). Our data
demonstrate that RUNX1, induced by VEGF released from PA treated hepatoma cells, is one of the key
responsible factors enhancing angiogenic activity in ECs.
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Figure 5. RUNX1 enhances the angiogenic activitiy of endothelial cells. (A) Representative tube 
formation images of HUVECs on matrigel (4× objective) transfected with RUNX1 expression 
plasmid (pRUNX1), control plasmid (pControl, empty vector) and/or incubated with VEGF (10 
ng/mL). (B) Average number of branch points per field and (C) tube length per field formed by 
HUVECs on matrigel under conditions described in (A) (n = 3). Data represent mean ± SD. *p < 0.05. 
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formation i ages of HUVECs on matrigel (4× objective) transfected with RUNX1 expression plasmid
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(B) Average number of branch points per field and (C) tube length per field formed by HUVECs on
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4. Discussion
In the current study, we report increased expression of RUNX1 in liver NPCs, presumably among
others in ECs of NASH livers. We describe a novel angiogenic and inflammatory role of RUNX1 in
NASH pathogenesis. Signals such as VEGF from PA-treated hepatocytes induce/increase the expression
of RUNX1 in ECs, resulting in an enhanced expression of angiogenic and adhesion molecules in these
cells, potentially augmenting increased leucocyte migration and adhesion.
Oxidative stress and inflammation-driven pathological angiogenesis is an important mechanism in
the progression of NAFLD from steatosis to NASH to cirrhosis and subsequently HCC [17]. Studies have
documented both increased and decreased hepatic expression of the angiogenic genes, such as VEGFA
and their cognate receptors in patients with NAFLD when compared to control tissues [5,18]. In our
study subjects, we did not observe a significant difference in the gene expression of known angiogenic
factors such as VEGFA, VEGFR1 and VEGFR2. However, we found a group of angiogenesis associated
genes to be differentially expressed in NASH. Among the transcription factors known to control these
DEGs, we became particularly interested in RUNX1, which was significantly positively correlated with
the histopathological features of NASH. PPARγ was another transcription factor, which was a part of
our validated DEGs and showed a good correlation with NAS, steatosis and inflammation degree of
the patients and the role of PPARγ in NAFLD is also well established [19].
RUNX1 is a salient factor that is known to control diversification between hematopoietic and
endothelial cell lineages [20,21]. Gain and loss of function in RUNX1 has been correlated with cancer
progression and metastasis, most notably in acute myeloid leukemia [22]. The role of RUNX1 in
enhancing TLR4-mediated inflammation has been demonstrated previously [23]. In our study, there
was an increased expression of RUNX1 in liver endothelial cells of NASH patients that significantly
correlated with severity of disease, hypothesizing a pathogenic role of endothelial-specific expression
of RUNX1 in NASH. Our findings are in concordance with those of Lam et al. who have also identified
RUNX1 as a gene upregulated in CD31-positive vascular ECs obtained from human proliferative
diabetic retinopathy fibrovascular membranes [24]. Although RUNX1 was not present in parenchymal
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liver cells, hepatocytes and cholangiocytes, we did find faint RUNX1 mRNA expression in Huh7 cells,
which is in concordance with the observation of a low RUNX1 nuclear expression in other hepatoma
cells such as human Hep3B and mouse AML12 [25]. Furthermore, RUNX1 was shown to regulate
TIMP1 (Tissue Inhibitor of Metalloproteinase 1) expression in hepatic stellate cells (HSCs) and to play a
role in activating HSCs in a mouse NASH model [14,26]. This may be because in earlier studies, they
solely analyzed RUNX1 in the HSCs and in our study, we focused on endothelial-specific expression of
RUNX1 and its potential role in NAFLD pathogenesis. However, it is highly possible that an increased
RUNX1 expression in HSCs or other NPCs such as Kupffer cells also contributes to NASH pathogenesis
via distinct mechanisms.
Performing in vitro cultures, we observed an increased expression of RUNX1 in HUVECs which
were treated with CM from PA treated hepatoma cells, indicating that non-saturated fatty acids and/or
high fat conditions, which are associated with oxidative stress and generation of reactive oxygen
species (ROS), may be inducing RUNX1 expression in HUVECs. Interestingly, a study has reported an
increase in mRNA expression of RUNX1 in liver tissue of a NAFLD guinea pig model, suggesting
a regulatory role of RUNX1 for organic cation transporter N1 (OCTN1) [27]. OCTN1 specifically
transports ergothioneine, a natural radical scavenger and therefore, augments its anti-oxidative and
anti-inflammatory properties. Previous studies in model organisms have shown that high glucose
levels act as a trigger for RUNX1 expression via ROS–mediated upregulation of hypoxia-inducible
factor 1 [24]. Therefore, RUNX1 expression seems to be triggered by cellular oxidative stress, dietary
factors and with regard to hepatic steatosis, this is mediated by VEGF and TGF-β, which were shown
to be released from hepatoma cells after PA treatment. The activation of RUNX1 by TGF-β and other
transcription factors such as SMAD1 has also been well reported in previous studies [28,29].
Overexpression of RUNX1 in ECs resulted in substantial increase in the expression of adhesion
molecules VCAM1 and PECAM1 and also that of CCL2, independent of additional treatment with VEGF.
Based on this finding, we propose a novel role of RUNX1 in the potential recruitment of inflammatory
cells in NASH, because VEGF is known to aggravate endothelial cell chemokine production in vitro
and in vivo and functions in the recruitment of monocytes and T cells [16]. Hence, both VEGF and
RUNX1 may act together as crucial angiogenic and pro-inflammatory inducers in NASH. We confirmed
the angiogenic properties of RUNX1 in ECs and show that RUNX1 may be an important downstream
effector of VEGF in mediating endothelial angiogenesis. However, angiogenic factors other than VEGF
may also be involved in RUNX1 regulation and need further characterization.
RUNX1 attenuation also led to a decrease in the expression of known RUNX1 target genes,
including CCL2, PI3KCA, PRKCE and eNOS. Furthermore, a decrease in angiogenic activity of ECs
while RUNX1 mRNA expression is silenced validated its role as an angiogenic modulator. The
contribution of RUNX1 towards angiogenesis in steatosis may also be deduced by the fact that
many of its target genes, including eNOS and PI3KCA, are known to be involved in various aspects
of angiogenesis, including EC proliferation, sprouting and vascular stabilization during hepatic
steatosis and inflammation in high fat diet mice [30,31]. PRKCE is already known to play a critical
role in mediating fat-induced hepatic insulin resistance through the buildup of diacylglycerol in
NAFLD [32–34]. CCL2 is mainly secreted by infiltrating inflammatory monocytes and HSCs in an
injured liver and is known to provide pro-angiogenic signals during chronic liver injury [35]. In our
study, CCL2 significantly correlated with the severity of human NASH and CCL2 release from ECs
was significantly altered by RUNX1 expression, adding novel insight into how RUNX1/CCL2 mediates
infiltration of inflammatory cells and angiogenesis in NASH. In addition, the expression of VEGFR1
was found to be attenuated in HUVECs after RUNX1 mRNA silencing, implicating that VEGFR1 may
be a vital factor downstream of RUNX1-mediated angiogenesis and disease progression in NAFLD [36].
However, whether VEGFR1 is a direct target of RUNX1 remains to be determined.
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5. Conclusions
To summarize, this study implicates the role of RUNX1 in aberrant liver angiogenesis and
inflammation in NASH, by modulating the expression of adhesion molecules and angiogenic properties
of ECs. The study not only identifies RUNX1 as a novel prospective therapeutic target and a biomarker
in NASH but also opens opportunities for exploration of the mechanisms of angiogenesis and
inflammation in NASH. In vivo RUNX1 depletion studies that would provide insight into the precise
contribution of RUNX1 towards inflammation and fibrosis in NASH are highly requisite.
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